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Abstract
Introduction The addition of taxanes (Ts) to chemotherapeutic
regimens has not demonstrated a consistent benefit in early-
stage breast cancer. To date, no clinically relevant biomarkers
that predict T response have been identified.
Methods A dataset of immunohistochemistry stains in 411
patients was mined to identify potential markers of response.
TLE3 emerged as a candidate marker for T response. To test the
association with T sensitivity, an independent 'triple-negative'
(TN) validation cohort was stained with anti-TLE3 antibody.
Results TLE3 staining was associated with improved 5-year
disease-free interval (DFI) in the overall cohort (n = 441, P <
0.004), in patients treated with cyclophosphamide (C),
methotrexate, and 5-fluorouracil (n = 72, P < 0.02), and in those
treated with regimens containing doxorubicin (A) and a T (n =
65,  P  < 0.04). However, no association was shown with
outcome in untreated patients (n = 203, P = 0.49) or those
treated with a regimen containing A only (n = 66, P = 0.97). In
the TN cohort, TLE3 staining was significantly associated with
improved 5-year DFI in all patients (n = 81, P  < 0.015), in
patients treated with AC + T (n = 45, P < 0.02), but not in
patients treated with AC (n = 17, P  = 0.81). TLE3 was
independent of tumor size, nodal status, and grade by bivariable
analysis in both cohorts.
Conclusions TLE3 staining is associated with improved DFI in
T-treated patients in two independent cohorts. Since the
validation study was performed in a TN cohort, TLE3 is not
serving as a surrogate for estrogen receptor or HER2
expression. TLE3 should be studied in large clinical trial cohorts
to establish its role in T chemotherapy selection.
Introduction
Breast cancer is a disease that shows significant biologic
diversity and a spectrum of clinical behaviors with important
differences in response to therapy. The application of molecu-
lar profiling to patient samples and the resultant evolving
molecular classification of breast cancer have identified at
least five subtypes, which can be distinguished by character-
istic gene expression profiles: two luminal subsets within
estrogen receptor (ER)-expressing tumors and three groups
within mostly ER- tumors (HER2, normal breast-like, and the
basal-like subtypes) [1]. In the clinical literature, the immuno-
histochemically defined 'triple-negative' (TN) (ER, progester-
one receptor (PR), and HER2) class has generated
considerable interest given their poor prognosis, an associa-
A: doxorubicin; AC: doxorubicin + cyclophosphamide; C: cyclophosphamide; CAF: cyclophosphamide, doxorubicin, and 5-fluorouracil; CCIH: Clear-
view Cancer Institute in Huntsville; CMF: cyclophosphamide, methotrexate, and 5-fluorouracil; EGFR: epidermal growth factor receptor; ER: estrogen 
receptor; F: 5-fluorouracil; HR: hazard ratio; IHC: immunohistochemistry; M: methotrexate; MRI: magnetic resonance imaging; P: carboplatin; PBS: 
phosphate-buffered saline; pCR: complete pathologic response; PR: progesterone receptor; RPCI: Roswell Park Cancer Institute; T: taxane; TLE: 
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tion with hereditary tumors, and the lack of established thera-
pies that target this subtype of breast cancer.
Numerous clinical trials and a large meta-analysis have demon-
strated a survival benefit from adjuvant chemotherapy in
women with breast cancer [2]. The taxanes, including paclit-
axel and docetaxel, are among the most active agents available
[3,4]. The mechanism of action of these drugs is related in part
to the stabilization of microtubules and the induction of G2/M
arrest, with subsequent apoptosis of tumor cells [5,6]. These
agents have become the standard of care for first-line treat-
ment of metastatic breast cancer and are frequently incorpo-
rated into both adjuvant and neoadjuvant anthracycline-
containing regimens. However, the addition of taxanes to cyto-
toxic regimens has not always demonstrated a consistent
improvement in outcomes, particularly in early-stage breast
cancer [7]. The variable benefit seen from taxane therapy is
likely the result of the heterogeneous nature of breast cancer.
We have endeavored to translate the gene expression-based
classification of carcinoma into immunohistochemistry (IHC)
reagents that can be used to discover and validate the rela-
tionship between tumor classification and clinically significant
phenotypes [8]. Using gene expression data to target our
efforts, we have generated over 700 novel rabbit antisera and
screened through these and hundreds of commercially availa-
ble antisera to identify those with utility in classifying breast
cancer. We have developed sets of antibodies termed 'panels
of diversity' which classify the biologic diversity of carcinoma,
and we have now focused on using these panels to discover
single or multiple reagents that can be combined using multi-
variate index assays to predict outcome for defined clinical
applications. We describe herein the nomination and valida-
tion of TLE3 as a novel biomarker of response to taxane ther-
apy in breast cancer. TLE3 is a member of the transducin-like
enhancer of split (TLE) family of proteins that have been impli-
cated in the tumorgenesis and classification of sarcomas
[9,10]. It is a transcriptional repressor homologous to dro-
sophila groucho proteins involved in repressing epithelial cell
fate determination [11,12]. It interacts with the Notch/WNT
pathway and appears to be periodically expressed during the
M phase of the cell cycle [13,14]. We validate its association
with outcome in taxane-treated patients using a qualitative IHC
test in a cohort of TN breast cancer patients.
Materials and methods
Patient samples and assembly of clinical datasets
Institutional breast cancer cohorts from the Clearview Cancer
Institute of Huntsville (CCIH) and the Roswell Park Cancer
Institute (RPCI) were used in this study. In all cohorts, patient
tumor paraffin blocks were assigned an anonymous unique
identifier linked to clinical databases that contained treatment
and outcome data. Institutional review board approval was
obtained for the use of patient blocks at each respective insti-
tute. A previously assembled dataset of IHC stains in 411
patients from the CCIH cohort diagnosed between 1989 and
2002 was mined to identify biomarkers of chemotherapy
response [8]. The RPCI Breast Cancer Database used for the
validation study contains all patients diagnosed with breast
cancer and treated with surgery at RPCI from January 1996 to
January 2006. Cases are entered into the database consecu-
tively as they are seen and treated. Eighty-one ER-, PR-, and
HER2- surgical cases were identified and paraffin blocks with
adequate tissue for analysis by tissue microarray (TMA) were
retrieved from the pathology archives. Patients who received
adjuvant and/or neoadjuvant chemotherapy were included.
For those patients who received neoadjuvant chemotherapy
and had a complete pathologic response (pCR) (no residual
tumor identified in the breast and axillary surgical specimens),
the diagnostic core biopsy specimen was stained without
incorporation into a TMA. Patients were excluded from the
study if their core biopsy was performed at an outside institu-
tion and showed a pCR (no tissue available at RPCI for analy-
sis). The TN immunophenotype for all cases was confirmed by
re-staining at RPCI. The clinical and pathologic characteristics
of the discovery, validation, and neoadjuvant cohorts were
extracted from the clinical records by chart review (Tables 1
and 2). When the data mining of the CCIH clinical dataset was
conducted, any adjuvant chemotherapy regimen that con-
tained both doxorubicin (A) and a taxane (T) (either paclitaxel
or docetaxel) was compared with any regimen containing A
without T. The prospectively designed validation study was
limited to comparing patients who received doxorubicin and
cyclophosphomide (AC) with those who received AC + T
(Table 3). Response to therapy in both the discovery and vali-
dation cohorts was assessed by the absence of local or dis-
tant recurrence and by the absence of new contralateral
breast cancer based on negative imaging studies and clinical
examination. In the neoadjuvant cohort, pCR was determined
by review of pathology reports that demonstrated no viable
tumor in the breast or in the axilla. Pre-treatment tumor size and
lymph node status were determined by chart review of the
physical exam findings and imaging reports. When imaging
reports were not available, archived films were reviewed with
the RPCI staff mammographer. Magnetic resonance imaging
(MRI) was not used extensively prior to 2003 at RPCI, but
when available, tumor size based on MRI findings was used to
determine the pre-treatment size of the primary tumor. If there
was a discrepancy between tumor size based upon physical
examination and imaging, physical examination was used to
determine pre-treatment stage.
Tissue arrays, immunohistochemistry, and scoring
Duplicate CCIH cohort TMA blocks that each contained single
0.6-mm cores sampled from representative paraffin blocks
from each patient were constructed, whereas the RPCI TMA
was constructed using duplicate cores from each patient in a
single block. TMA sections were dehydrated by submersion in
xylene three times for 10 minutes each to remove paraffin,
rinsed three times in 100% ethanol and two times in 95% eth-Available online http://breast-cancer-research.com/content/11/2/R17
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anol, and boiled in a microwave for 11 minutes in 10 μM buff-
ered citrate (pH 6.0). Slides were allowed to cool to room
temperature and were rinsed in distilled water and then in
phosphate-buffered saline (PBS). Slides were dipped in
0.03% hydrogen peroxide, rinsed with PBS, and stained using
antibody diluted to appropriate titer in Dako Diluent (DakoCy-
tomation, Glostrup, Denmark) for one hour at room tempera-
ture. As a control for staining quality and to select titer,
candidate dilutions were first tested on a small 'titer' tissue
array that contained positive and negative breast cancer cases
Table 1
Clinical and pathologic characteristics of the Clearview Cancer Institute in Huntsville discovery cohort and the Roswell Park Cancer 
Institute validation cohort
CCIH RPCI
Number Percentage Number Percentage
Total patients 411 100 81 100
Age < 50 years 117 28 33 41
≥ 50 years 294 72 47 58
Unknown 0 0 1 1
T u m o r  s i z e T 0 1011
T1 207 50 38 47
T2 157 38 26 32
T3 19 5 10 12
T4 11 3 3 4
T unknown 16 4 3 4
Lymph node status N0 234 57 39 48
N1 162 39 27 33
N 2 7256
N3 0 0 10 12
N unknown 8 2 0 0
Stage I 170 41 25 31
II 206 50 36 44
III 35 9 19 23
Unknown 0 0 1 1
Grade 1 53 13 0 0
2 149 36 7 9
3 132 32 70 86
Unknown 77 19 4 5
ER status ER+ 276 67 0 0
ER- 131 32 81 100
ER unknown 4 1 0 0
HER2 status HER2+ 62 15 0 0
HER2- 333 81 81 100
HER2 unknown 16 4 0 0
Recurrence 108 26 55 68
D e a t h 5 81 41 21 5
Data include 12 patients from the larger Roswell Park Cancer Institute (RPCI) validation study. See Results section for details. CCIH, Clearview 
Cancer Institute in Huntsville; ER, estrogen receptor.Breast Cancer Research    Vol 11 No 2    Kulkarni et al.
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and tumor-derived cell lines suspended in paraffin. IHC analy-
sis for TLE3 was performed using a polyclonal affinity-purified
antibody at a titer of 1:200. Secondary antibody was applied
for 1 hour and staining was visualized using the DakoCytoma-
tion Envision staining kit in accordance with the instructions of
the manufacturer. A case was scored as positive if greater
than 30% of the tumor cell nuclei showed staining, regardless
of the staining intensity. Cases without evaluable tumor on any
available specimen were removed from the study. Staining
with TLE3 in breast cohorts showed differences in a fraction
of cases stained as well as variation in intensity of staining.
However, there was a subjectively clear delineation between
sporadic staining of nuclei and near-homogenous staining
(staining of all nuclei). An example of IHC staining for TLE3 is
shown in Figure 1. A variety of tumors with expected positives
and negatives served as controls. A 30% cutoff was selected
to formalize this subjective impression without consideration
of a relationship to clinical outcome when the initial cohort was
evaluated. This staining rule was prospectively designated
prior to staining the validation cohort. Disagreements between
replicates were reviewed using an online image database and
'consensus' staining scores assigned prior to clinical data
cross-referencing. Staining of TLE3 was performed on tissue
obtained from the surgical resection in the discovery and vali-
dation cohorts. In the subset of cases which received neoad-
juvant therapy at RPCI and in which no tissue was available in
the final surgical specimen (pCR), TLE3 staining was per-
Table 2
Clinical and pathologic characteristics of the Roswell Park 
Cancer Institute neoadjuvant cohort
Roswell Park Cancer Institute neoadjuvant
Number Percentage
Total patients 23 100
Age < 50 years 13 57
≥ 50 years 10 43
Unknown 0 0
Tumor size T0 3 13
T1 6 26
T2 7 30
T3 7 30
T4 0 0
T unknown 0 0
Node status N0 7 30
N1 5 22
N2 5 22
N3 6 26
N unknown 0 0
Stage I 0 0
II 10 43
III 13 57
Unknown 0 0
ER status ER+ 00
ER- 23 100
ER unknown 0 0
Grade 1 0 0
22 9
31 7 7 4
Unknown 4 17
HER2 status HER2+ 00
HER2- 23 100
HER2 unknown 0 0
Recurrence 11 48
Death 9 39
ER, estrogen receptor.
Table 3
Chemotherapy regimens used in the Clearview Cancer Institute 
in Huntsville and Roswell Park Cancer Institute cohorts
Regimen Number
CCIH
AC 44
CAF 22
AC + pT 43
AC + dT 11
A + dT 7
CAF + pT 2
AC + pT + dT 2
CMF 72
RPCI
AC 17
AC + pT 33
AC + dT 12
pTa 1
P + pTa 1
Since the Roswell Park Cancer Institute (RPCI) cohort had more 
standardized treatment (97% had AC or AC + T), the two patients 
who did not receive AC as part of their regimen were filtered from the 
analysis. aPatients not included in the analysis. A, doxorubicin; AC, 
doxorubicin + cyclophosphamide; CAF, cyclophosphamide, 
doxorubicin, and 5-fluorouracil; CCIH, Clearview Cancer Institute in 
Huntsville; CMF, cyclophosphamide, methotrexate, and 5-
fluorouracil; dT, docetaxel; P, carboplatin. pT, paclitaxel; T, taxane 
(paclitaxel or docetaxel).Available online http://breast-cancer-research.com/content/11/2/R17
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formed on the diagnostic core biopsy obtained prior to treat-
ment.
Statistical considerations
The TLE3 biomarker was identified as a candidate predictive
marker for taxane response in a large survey of biomarkers in
the CCIH cohort and therefore a correction for multiple testing
would be required in order to assess the significance of its
association with outcome in the CCIH discovery study. The
reported P values reflect significance for uncorrected associ-
ations. The study at RPCI was prospectively assembled to test
the hypothesis from the CCIH cohort. The RPCI taxane arm (n
= 45) was 80% powered to test the association with outcome
found in the CCIH taxane-treated arm, whereas the AC arm (n
= 17) was 36% powered to test an association with outcome
if it existed. Independence of TLE3 staining from other clinical
and pathologic prognostic parameters was tested by placing
TLE3 in a Cox proportional hazards model with each variable
in a bivariable model. Tumor response was calculated as the
difference between clinical tumor size estimated prior to neo-
adjuvant treatment subtracted from that estimated after treat-
ment. The relationship between recurrence within 5 years of
diagnosis and tumor response was assessed using S-plus
software (Tibco Software Inc., Palo Alto, CA, USA) by both a
Cox proportional hazards and logistic regression model. The
coefficients generated by the latter were used in Excel (Micro-
soft Corporation, Redmond, WA, USA) to generate the logis-
tic regression curve relating probability of recurrence with
tumor response. The predicted association between TLE3
staining and stronger response to treatment was confirmed
using a Student t test with significance tested using a one-
sided P value. All univariate and bivariate Cox proportional haz-
ard ratios (HRs), the Fisher exact test, and associated P values
were calculated using S-plus software.
Results
Discovery of TLE3 as a candidate taxane predictive 
biomarker
Our group has undertaken a large-scale project to screen
commercially available and gene expression-targeted novel
antisera for utility in classifying breast cancer and identifying
individual reagents or combinations of reagents with clinical
utility as biomarkers. The identification of TLE3 as a candidate
predictive marker for chemotherapy response came from
exploration of an existing dataset of IHC stains performed on
a single-institution cohort assembled at the CCIH [8]. This
cohort of 411 patient samples was stained with over 100
selected antisera (out of approximately 1,000 candidates
screened as candidate breast cancer classifiers on non-clini-
cal breast cancer TMAs). TLE3 protein expression was found
to be associated with lower risk of recurrence in patients
treated with cytotoxic chemotherapy (HR = 0.5, P = 0.013).
However, no association between TLE3 expression and recur-
rence was observed in patients treated without adjuvant
chemotherapy (HR = 0.8, P = 0.49) (Figure 2a,b). Upon fur-
ther exploration of the data, TLE3 expression was found to be
associated with an improved outcome in those patients who
received adjuvant cytotoxic chemotherapy with CMF (Figure
2c) or regimens containing AC plus a taxane (n = 65, HR =
0.1, P < 0.04) (Figure 2d). No association between TLE3
expression and outcome was seen in patients treated with reg-
imens that contained AC alone (for example, AC or CAF, n =
66, HR = 1.03, P = 0.97) (Figure 2e). Ki67/MIB1 staining, a
marker of proliferation status, was not associated with chemo-
therapy response or TLE3 expression (data not shown). In
bivariable analysis of taxane-treated patients, TLE3 staining
was significantly associated with outcome in the presence of
all available clinical and pathologic parameters, including ER
and HER2 status (Table 4).
Independent validation in 'triple-negative' breast tumors
Since a large number of antibodies were used to stain the
CCIH cohort, the significance of the association between
TLE3 expression and response to taxane therapy is con-
founded by multiple-hypothesis testing. To independently vali-
date the association between TLE3 staining and outcome
among taxane-treated patients, we assembled a new 81-
patient TN tissue array cohort using archived paraffin blocks of
surgical specimens from RPCI. In this prospectively designed
study, TLE3 staining was again associated with favorable out-
come but only when patients were treated with an AC regimen
that included a taxane (n = 56, HR = 0.15, P = 0.018) as
opposed to AC alone (n = 17, HR = 0.76, P = 0.97) (Figure
3a,b). The association with outcome in taxane-treated patients
was present regardless of stage at diagnosis (Figure 3c–e). In
bivariable analysis with TLE3+, only tumor size trended toward
an independent association with outcome in taxane-treated
patients whereas age, node status, pathologic grade, and
Ki67 and epidermal growth factor receptor (EGFR) expression
were not significant (Table 3).
Figure 1
TLE3+ immunohistochemical staining gives a stronger pattern in the  nucleus of breast carcinoma cells than TLE3- immunohistochemical  staining does TLE3+ immunohistochemical staining gives a stronger pattern in the 
nucleus of breast carcinoma cells than TLE3- immunohistochemical 
staining does.Breast Cancer Research    Vol 11 No 2    Kulkarni et al.
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Although this study was designed primarily to explore the utility
of TLE3 as a candidate biomarker in the adjuvant setting, we
also assembled available patient samples for assessing
whether it might be useful in the neoadjuvant setting to predict
those patients who would respond to pre-operative taxane
treatment. Twelve patients from the original RPCI study who
received neoadjuvant taxane therapy were combined with 11
TN patients who were originally excluded from the study
because not enough viable tumor tissue was available in the
post-neoadjuvant surgical specimen for tissue procurement.
Stains were performed on the pre-treatment diagnostic core
biopsies for these 11 new patients. In this study of neoadju-
vant taxane-treated patients (n = 23), TLE3 expression was
also associated with favorable outcome (recurrence: HR =
0.12, P = 0.0093; survival: HR = 0.11, P = 0.042) (Figure 4).
Available archived clinical records and imaging studies were
reviewed to approximate the change in tumor size in response
to neoadjuvant therapy for 21 of the study patients. Tumor size
reduction was highly correlated with likelihood of recurrence
at 5 years (HR = 1.56, P = 0.0001), and a significant associ-
ation between staining with TLE3 and decrease in tumor size
was confirmed (Figure 5, t test one-sided P value < 0.04).
Discussion
In this study of breast cancer patients receiving adjuvant
chemotherapy at two independent institutions, TLE3 staining
was associated with improved disease-free survival in patients
receiving a taxane-containing regimen as opposed to anthra-
cycline without taxane. The CCIH cohort in which the associ-
ation between taxane treatment and outcome was first
discovered was comprised of both ER-expressing and ER-
patients. The RPCI TN cohort was prospectively assembled as
an independent validation study to test the association
between TLE3 staining and taxane sensitivity discovered in the
CCIH cohort. The TN cohort was chosen for three reasons: (a)
to remove the confounding effects of ER and HER2, (b) tax-
anes are routinely given as standard of care in this population,
and (c) the risk of recurrence is higher in TN breast cancer and
Figure 2
Kaplan-Meier plots in the Clearview Cancer Institute in Huntsville 'discovery' cohort Kaplan-Meier plots in the Clearview Cancer Institute in Huntsville 'discovery' cohort. Patients in this cohort were treated with (a) any adjuvant chem-
otherapy regimen, (b) no adjuvant chemotherapy, (c) CMF, (d) AC (± F) ± taxane, (e) AC (± F) but not a taxane. AC, doxorubicin + cyclophospha-
mide; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; F, 5-fluorouracil.Available online http://breast-cancer-research.com/content/11/2/R17
Page 7 of 10
(page number not for citation purposes)
therefore a large number of disease progression events were
available for analysis. Although patients in the CCIH cohort
were treated with variable chemotherapeutic regimens and
anti-hormonal treatment for ER+ patients, the association of
TLE3 with taxane sensitivity was independent of stage, grade,
and ER and HER2 status. In the validation study, in which
treatment was standardized to AC or AC + T, the association
between TLE3 staining and treatment with a taxane-containing
regimen was confirmed and was found to be independent of
Ki67/MIB1 and EGFR expression, stage, and grade (the
cohort was predominantly high-grade overall). As this cohort
was also confirmed to be ER- and HER2- by re-staining, TLE3
is not acting as a surrogate for proliferation, HER2, or ER.
The association of TLE3 with outcome was also apparent in
the subset of patients who received neoadjuvant taxanes as
part of their regimen. In addition, retrospective review of tumor
response to treatment showed a significant association
between TLE3 expression and decrease in tumor size after
neoadjuvant treatment. Unfortunately, our group was too small
to test a significant association between pCR and TLE3
expression. Of the eleven core biopsy samples for which
tumor material was apparently completely depleted by neoad-
juvant therapy, seven were TLE3+ and only one of these seven
ultimately recurred. While these data are exploratory and do
not incorporate more recent quantitative methods of measur-
ing tumor response, the possibility of using TLE3 as tool to
predict response in the neoadjuvant setting is intriguing and
warrants further study in a prospective trial [15].
TLE3 is a transcriptional repressor that appears to be periodi-
cally expressed during the M phase of the cell cycle [13,14].
Other TLE family members have been implicated in tumoro-
genic pathways, and TLE1 when overexpressed leads to lung
adenocarcinoma in mice and also has been confirmed as a
biomarker able to differentiate synovial sarcomas [10,16,17].
TLE family members have been shown to interact with the
Notch pathway members and be phosphorylated by mitogen-
activated protein kinase in the nucleus in response to EGFR
signaling, potentially modulating Notch pathway signaling
[18,19]. More recently, TLE3 was identified in a screen for
genes causing estrogen independence in breast cancer cell
lines and RNA levels further shown to be associated with pro-
gression-free survival in ER-expressing patients treated with
tamoxifen as first-line treatment for metastatic disease [20,21].
In this study, TLE3 expression was associated with both meth-
otrexate and taxane sensitivity in the discovery cohort and was
confirmed to be associated with taxane sensitivity in the valida-
tion cohort. This raises the possibility that, as opposed to
being related only to taxane therapy, it may be a candidate
marker of sensitivity to cell cycle-targeted cytotoxic therapeu-
tics. By IHC, it is expressed exclusively in the nucleus in a sub-
set of carcinoma cases. Its pattern of expression both within a
single tumor and across a large number of tumor cases is dis-
tinct from that of classic proliferation markers such as Ki67.
Since TLE proteins are known to interact directly with chroma-
tin and chromatin-associated proteins, it may identify cells in a
differentiation state particularly sensitive to cell cycle perturba-
tion [22]. Further studies are needed to explore whether TLE3
Table 4
Bivariable analysis of TLE3 with clinical and pathologic prognosticators
CCIH RPCI
TLE3 Clinical variable TLE3 Clinical variable
Variable HR P value HR P value HR P value HR P value
Age 0.114 0.038 1.002 0.94 0.15 0.02 0.98 0.52
Tumor size 0.125 0.047 1.026 0.91 0.13 0.01 1.18 0.07
Node status 0.123 0.045 0.423 0.22 0.14 0.02 1.04 0.21
Stage 0.010 0.035 2.24 0.25 0.15 0.02 1.58 0.25
Grade 0.125 0.048 0.95 0.83 0.15 0.02 0.61 0.29
Ki67 0.118 0.041 0.82 0.74 0.09 0.03 0.53 0.45
EGFR 0.09 0.028 2.1 0.37 0.15 0.02 0.63 0.66
ER 0.116 0.042 0.956 0.94 NA NA NA NA
HER2 0.099 0.028 5.92 0.01 NA NA NA NA
TLE3 was tested for independence in the Clearview Cancer Institute in Huntsville (CCIH) and Roswell Park Cancer Institute (RPCI) triple-negative 
cohorts with a range of standard clinical prognosticators. Independence was tested by placing TLE3 in a Cox proportional hazards model with 
each of the above variables. In all equations, TLE3 remained a significantly independent predictor of taxane sensitivity (P values ranging from 
0.008 to 0.048, hazard ratios [HRs] from 0.05 to 0.29). In the validation cohort, tumor size, number of metastatic nodes, and stage remain 
independent prognosticators to TLE3+, while age trends in the right direction. Grade and Ki67 are not independent prognosticators; this is likely 
due to the fact that the cohort consists almost entirely of high-proliferative tumors. EGFR, epidermal growth factor receptor; ER, estrogen 
receptor; NA, not applicable.Breast Cancer Research    Vol 11 No 2    Kulkarni et al.
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is only a marker of sensitive cells or whether it can be impli-
cated more directly in sensitizing cells to chemotherapy-medi-
ated cell death.
Taxanes are one of the most active agents against breast can-
cer and are routinely used in metastatic, adjuvant, and neoad-
juvant settings. Results from a number of large randomized
trials demonstrate that the use of both paclitaxel and docetaxel
can result in improved outcomes in women with breast cancer
of all stages [3,4,6,7]. A number of studies have looked at clin-
ical and pathologic parameters that might predict response to
taxanes, most notably the candidate biomarker tau, but evi-
dence in support of the use of these biomarkers is still prelim-
inary [23,24]. A recent study by Hayes and colleagues [25]
suggested that HER2+ breast tumors may gain increased clin-
ical benefit from treatment with taxanes. However, other stud-
ies have shown no association between response to taxanes
and HER2 overexpression [26]. Taxane-containing regimens
have significant short-term toxicity compared with the conven-
tional anthracycline-containing combinations, particularly
related to myelosuppression, peripheral neuropathy, and
hypersensitivity reactions. Long-term toxicities from taxane use
are still largely unknown. At present, no biomarkers associated
with taxane response have been validated to a confidence
level that would allow them to be incorporated into standard
practice.
The discovery of TLE3 as a candidate biomarker of taxane sen-
sitivity in the CCIH study is confounded by the use of a variety
of therapies and exploration of a large number of candidate
Figure 3
Kaplan-Meier plots depicting recurrence in the Roswell Park Cancer Institute validation 'triple-negative' cohort Kaplan-Meier plots depicting recurrence in the Roswell Park Cancer Institute validation 'triple-negative' cohort. Patients in this cohort were treated 
with (a) doxorubicin + cyclophosphamide (AC) without a taxane or (b) AC plus a taxane. Patients treated with AC plus a taxane were furthered fil-
tered to (c) stage II or greater, (d) stage IIB or greater, or (e) stage III or greater.Available online http://breast-cancer-research.com/content/11/2/R17
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biomarkers in this hypothesis-generating study. Although the
validation study was relatively small and specifically the AC
arm was underpowered to test for an interaction between
TLE3 and taxane treatment, the confirmation of an association
of TLE3 with outcome in taxane-treated patients while show-
ing no association with outcome in patients treated only with
anthracylines is consistent with the predictive hypothesis gen-
erated in the CCIH study. The consistency of the findings
across cohorts and the strength of the association with out-
come in predominantly high-grade tumors treated with taxanes
in the independent TN validation study support TLE3 as a
biomarker of response to taxane therapy. We believe TLE3
should be studied in larger clinical trial populations to further
assess its potential as a predictive marker for taxane therapy in
breast cancer.
Conclusions
This study of IHC staining with TLE3 antibody in breast carci-
noma and its association with outcome supports the hypothe-
sis that increased TLE3 expression may predict those patients
who will respond to taxane therapy. Furthermore, it is remark-
able that, in the validation study, TLE3 staining was associated
with response to taxane therapy in women with aggressive TN
disease in which there is an absence of established molecular
targets for targeted therapy. Clearly, the identification of high-
quality biomarkers capable of identifying women with a high
likelihood of response to taxanes would represent a significant
Figure 4
Kaplan-Meier plots depicting (a) 5-year recurrence and (b) 5-year overall survival among the patients treated neoadjuvantly with doxorubicin + cyclo- phosphamide plus a taxane in the Roswell Park Cancer Institute triple-negative cohort Kaplan-Meier plots depicting (a) 5-year recurrence and (b) 5-year overall survival among the patients treated neoadjuvantly with doxorubicin + cyclo-
phosphamide plus a taxane in the Roswell Park Cancer Institute triple-negative cohort.
Figure 5
Logistic regression showing the relationship between the change in tumor size in centimeters (measured before and after neoadjuvant chemother- apy) and the likelihood of recurrence Logistic regression showing the relationship between the change in tumor size in centimeters (measured before and after neoadjuvant chemother-
apy) and the likelihood of recurrence. The circles represent the actual patients, color-coded according to TLE3 expression and plotted at either 0 
(recurrence-free) or 1 (recurred). A large reduction in tumor size from neodadjuvant therapy correlated with lack of recurrence and was enriched for 
TLE3+ patients (bottom left corner).Breast Cancer Research    Vol 11 No 2    Kulkarni et al.
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advance in our ability to effectively treat women with breast
cancer. Additional study of TLE3 as a candidate biomarker is
warranted in larger clinical trial populations to confirm these
findings.
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